Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01481116 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes
A Phase 3 study, sponsored by Takeda.
- Terminated
- Registry status
- Phase 3
- Development phase
- 2,454
- Enrollment target
NCT01481116 is a Phase 3 study that was terminated before completion, run by Takeda. The registered enrollment target is 2,454 participants.
The verdict
NCT01481116, a Phase 3 study, was terminated before completion, sponsored by Takeda.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 2,454 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the efficacy and safety of TAK-875, once daily (QD), plus metformin compared to glimepiride plus metformin in participants with type 2 diabetes mellitus (T2DM). The purpose of this study is to determine the efficacy and safety of TAK-875, once daily (QD), plus metformin compared to glimepiride plus metformin in participants with type 2 diabetes mellitus (T2DM).
Interventions
- DRUG Glimepiride
- DRUG TAK-875
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,454 participants |
| Start Date | 2012-01 |
| Est. Completion | 2014-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01481116
The ClinicalTrials.gov registry entry for NCT01481116 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 2,454 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Glimepiride is the first listed.
NCT01481116 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01481116 about?
NCT01481116 is a clinical study titled "Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes". The purpose of this study is to determine the efficacy and safety of TAK-875, once daily (QD), plus metformin compared to glimepiride plus metformin in participants with type 2 diabetes mellitus (T2DM). The purpose of this study is to determine the efficacy and safety of TAK-875, once daily (QD), p...
What is the current status of trial NCT01481116?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 2,454 participants. The study started on 2012-01. Estimated completion is 2014-04.
What interventions are being tested in trial NCT01481116?
The interventions under investigation include: Glimepiride (DRUG), TAK-875 (DRUG).
Who is sponsoring clinical trial NCT01481116?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.